RenovoRx, Inc. (RNXT)
1.20
+0.01
(+0.84%)
USD |
NASDAQ |
Oct 16, 11:57
RenovoRx SG&A Expense (TTM) : 9.594M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 9.594M |
| March 31, 2026 | 8.201M |
| December 31, 2025 | 7.052M |
| September 30, 2025 | 5.92M |
| June 30, 2025 | 5.37M |
| March 31, 2025 | 5.34M |
| December 31, 2024 | 4.988M |
| September 30, 2024 | 4.891M |
| June 30, 2024 | 5.067M |
| March 31, 2024 | 5.025M |
| December 31, 2023 | 5.729M |
| September 30, 2023 | 6.121M |
| June 30, 2023 | 6.082M |
| Date | Value |
|---|---|
| March 31, 2023 | 5.856M |
| December 31, 2022 | 5.649M |
| September 30, 2022 | 5.51M |
| June 30, 2022 | 4.823M |
| March 31, 2022 | 3.929M |
| December 31, 2021 | 2.631M |
| September 30, 2021 | 1.559M |
| June 30, 2021 | 1.131M |
| March 31, 2021 | 1.049M |
| September 30, 2020 | 0.631M |
| June 30, 2020 | 0.448M |
| March 31, 2020 | 0.248M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Enanta Pharmaceuticals, Inc. | 37.75M |
| Travere Therapeutics, Inc. | 396.39M |
| REGENXBIO, Inc. | 85.56M |
| Krystal Biotech, Inc. | 159.89M |
| ACADIA Pharmaceuticals, Inc. | 620.29M |